Maha Ghazzi

Prior to MMS, she has worked at Pfizer, most recently as Executive Director/Development Team Leader. In this role, she was responsible for leading late stage development teams for several candidates in thrombosis (apixaban) and atherosclerosis (Biologics: HDL infusions). Dr. Ghazzi also provided cross functional leadership to develop an integrated strategy, communicate with senior management for endorsement, and ensure timely implementation of agreed plans. She worked closely with opinion leaders and experts in the field in order to ensure that the clinical development plan was optimized to meet regulatory and commercial needs. Additionally, she interacted with regulatory agencies (FDA, CHMP, and PMDA) for alignment on clinical and non-clinical development plans.

With MMS, Dr. Ghazzi supports sponsors with distinct leadership tasks and leads teams through management of special safety topics, execution of specialized task forces, and assists internal and external teams with data summarizations for submissions. She reviews clinical sections of submissions and other documents and serves in a leadership capacity for various summarization teams. Additionally, she provides training to the in-house staff on clinical data interpretations.

Dr. Maha Ghazzi earned her Doctor of Pharmacy at the University of Michigan College of Pharmacy in Ann Arbor, Mich.

Suggested For You

news

November 19th, 2024

MMS Recognized as a Top Workplace by Detroit Free Press and USA Today Network for the Fourth Consecutive Year

perspectives

November 12th, 2024

REMS Logic Modeling: Applying FDA Guidance from November 2024 CDER Webinar

news

November 8th, 2024

MMS Named a Finalist in the 2024 Fierce CRO Awards for Leadership in Regulatory Compliance

perspectives

November 6th, 2024

How to Successfully Manage Rescue Studies and Turn Around Clinical Trials Facing Failure

perspectives

October 29th, 2024

Why Outsourcing QC of Regulatory and Medical Writing Documents is a Competitive Advantage for Large Pharma Companies

perspectives

October 22nd, 2024

Choosing the Right Clinical Trial Design: A Crucial Step in Protocol Development

perspectives

October 15th, 2024

Putting the Action in Diversity Action Plans and the Real-Time Data Visualization Technology Needed to Ensure It Happens

news

October 15th, 2024

MMS Recognized with EcoVadis Bronze Medal for Leadership in ESG Sustainability Efforts as a Leading Clinical Research Organization (CRO)

perspectives

October 8th, 2024

Diversity Action Plan Guidance Part I: Implications for Sponsors

webinar

October 22nd, 2024

Optimal Strategies to Protect Commercially Confidential Information (CCI) in Clinical Documents and Report Trial Results Under Revised EU-CTIS Transparency Rules

perspectives

September 30th, 2024

Meet the Leaders Driving MMS’s European Growth

perspectives

September 30th, 2024

The Future of Data Management and Biostatistics: Trends and Technologies Shaping the Industry